Complications of Diabetes: Retinopathy, Nephropathy, and Neuropathy — How to Prevent Them

Chronic complications of type 2 diabetes develop silently, often for years before they become symptomatic. According to data from the Italian National Institute of Health (2024), in Italy 20-30% of people with diabetes develop at least one microvascular complication during the course of the disease. Diabetic retinopathy, nephropathy, and neuropathy share a common mechanism: damage to small blood vessels (microangiopathy) caused by prolonged exposure to hyperglycemia. Understanding how they develop and how to prevent them is the basis for informed diabetes management.

The good news is that these complications are largely preventable—or significantly delayed—by effective glycemic control. The UKPDS (UK Prospective Diabetes Study, NEJM 1998), one of the largest diabetes studies ever conducted on over 5,000 patients, showed that reducing HbA1c by 1% reduces microvascular complications by 37%. The problem is that most of the damage accumulates during the pre-diabetic phase and in the early years of the disease, often in the absence of symptoms and without standard tests detecting it.

Comparing the three microvascular complications

Diabetic retinopathy: vision damage no one sees coming

Diabetic retinopathy is the most common cause of blindness in working-age people in developed countries. In Italy, it is estimated to affect 20-30% of people with long-standing type 2 diabetes (SID, 2024). The mechanism is progressive: chronic hyperglycemia damages retinal capillaries, causing microaneurysms, punctate hemorrhages, hard and soft exudates. In proliferative forms—the most severe—new fragile and abnormal vessels form, which can lead to vitreous hemorrhage and retinal detachment.

The most insidious characteristic is the absence of symptoms in the early stages: vision can remain intact until the damage is already extensive. For this reason, an annual fundus exam with pupillary dilation is recommended for all diabetics, even in the absence of visual disturbances. Early diagnosis allows for treatment with laser photocoagulation or intravitreal anti-VEGF injections, which are effective in preserving vision.

Factors that accelerate retinopathy: uncontrolled arterial hypertension, smoking, dyslipidemia, pregnancy, duration of the disease. Optimal blood pressure control (target <130/80 mmHg for diabetics, ESC 2024) slows progression independently of glycemic control.

Diabetic nephropathy: the silent kidney that deteriorates

Diabetic nephropathy is the leading cause of chronic kidney failure requiring dialysis in Italy and Europe. It affects about 20-40% of long-standing diabetics. Progression follows well-defined stages: from stage 1 (glomerular hyperfiltration, absence of proteinuria) to stage 5 (end-stage renal disease). Progression typically takes 10-20 years—but can be significantly slowed if detected early.

The most important early marker is microalbuminuria: the presence of small amounts of albumin in the urine (30-300 mg/g of creatinine). Detected at this stage, progression can be slowed with nephroprotective drugs—ACE inhibitors or sartans as a first choice, supported by new SGLT2 inhibitors (empagliflozin, dapagliflozin) which have demonstrated nephroprotective effects independent of glycemic control. Urinary albumin testing is recommended annually for all diabetics from diagnosis.

Beware of nephrotoxic drugs: NSAIDs, iodinated contrast media, aminoglycosides—to be used with extreme caution in diabetics with nephropathy, always after evaluating current kidney function.

Diabetic neuropathy: nerves slowly shutting down

Diabetic peripheral neuropathy is the most common complication of diabetes, affecting up to 50% of long-standing diabetics (ADA, 2024). Typical manifestations include tingling, burning, paresthesias, and reduced sensation in a "stocking-glove" distribution—symmetrical, starting from the feet and ascending towards the knees. In painful forms, it can be debilitating, with neuropathic pain worsening at night.

Less known but equally important is autonomic neuropathy, which can cause: orthostatic hypotension (dizziness when standing up), gastroparesis (delayed gastric emptying with unpredictable glycemic fluctuations), erectile dysfunction, sweating alterations, and resting tachycardia. Cardiovascular autonomic neuropathy increases the risk of arrhythmias and sudden cardiac death in diabetics.

There is no therapy that reverses existing neurological damage—but glycemic control halts its progression. For neuropathic pain, EFNS guidelines recommend gabapentin, pregabalin, duloxetine, or low-dose tricyclic antidepressants.

How glycemic control prevents complications: the evidence

The scientific evidence is convergent and robust. Here are the key data:

• UKPDS (1998, NEJM): 1% reduction in HbA1c → retinopathy -37%, nephropathy -24%
• DCCT (1993, NEJM): intensive control reduces retinopathy by 76% and neuropathy by 60% in type 1 diabetes
• ADVANCE (2008): HbA1c target <6.5% reduces nephropathy by 21% compared to the standard target
• Steno-2 Study: multifactorial treatment (glycemia + blood pressure + lipids) reduces microvascular complications by 50%
• DECODE Study (ESC, 2001): 2-hour postprandial glucose is an independent and more powerful predictor of cardiovascular mortality than fasting glucose

This last piece of data is particularly relevant: postprandial monitoring—often overlooked in favor of fasting glucose alone—is crucial for identifying the glycemic peaks that cause cumulative microvascular damage. Many people have "acceptable" fasting glucose but postprandial peaks that regularly exceed 140-180 mg/dL, invisible to standard tests.

Frequently asked questions

If I've only recently been diagnosed with diabetes, do I need to worry about complications already?

Unfortunately, yes. Microvascular complications can begin to develop during the pre-diabetic phase, when postprandial glycemic peaks are high but fasting glucose and HbA1c are still within the normal range. For this reason, screening for complications should begin at diagnosis and, for modifiable risk factors (blood pressure, lipids, glucose), even earlier. Primary prevention is worth much more than any secondary therapy.

Can diabetic retinopathy regress with good glycemic control?

In the early stages (mild-moderate non-proliferative retinopathy), a significant improvement in glycemic control can stabilize or improve retinal signs. In advanced stages, structural damage tends to be irreversible, but good control significantly slows progression. Laser photocoagulation and anti-VEGFs are effective if applied promptly, before retinal detachment.

Is tingling in the feet always diabetic neuropathy?

Not necessarily. Differential diagnosis includes vitamin B12 deficiency neuropathies (worsened by long-term metformin), lumbar stenosis, alcoholic neuropathy, hypothyroidism, and other causes. A complete neurological evaluation is essential before attributing any symptom to diabetic neuropathy. The doctor will use the Semmes-Weinstein monofilament (10 grams) and a tuning fork to test protective sensation.

The most effective measure to prevent diabetes complications is controlling postprandial glycemic peaks. The G1 Pro VitaeChek Glucose Meter measures blood glucose in 5 seconds with MARD accuracy <5%, is CE Class IIa and ISO 15197:2013 certified, and automatically sends data to the app for trend monitoring. 2-year warranty · Free shipping.